These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27035404)

  • 1. Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study.
    Zajecka JM; Fava M; Shelton RC; Barrentine LW; Young P; Papakostas GI
    J Clin Psychiatry; 2016 May; 77(5):654-60. PubMed ID: 27035404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
    Papakostas GI; Shelton RC; Zajecka JM; Bottiglieri T; Roffman J; Cassiello C; Stahl SM; Fava M
    J Clin Psychiatry; 2014 Aug; 75(8):855-63. PubMed ID: 24813065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
    Papakostas GI; Shelton RC; Zajecka JM; Etemad B; Rickels K; Clain A; Baer L; Dalton ED; Sacco GR; Schoenfeld D; Pencina M; Meisner A; Bottiglieri T; Nelson E; Mischoulon D; Alpert JE; Barbee JG; Zisook S; Fava M
    Am J Psychiatry; 2012 Dec; 169(12):1267-74. PubMed ID: 23212058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL; Kindermann SL; Hou Q; Thase ME
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
    Shelton RC; Pencina MJ; Barrentine LW; Ruiz JA; Fava M; Zajecka JM; Papakostas GI
    J Clin Psychiatry; 2015 Dec; 76(12):1635-41. PubMed ID: 26613389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball SG; Ferguson MB; Martinez JM; Pangallo BA; Nery ES; Dellva MA; Sparks J; Zhang Q; Liu P; Bangs M; Goldberger C
    J Clin Psychiatry; 2016 May; 77(5):635-42. PubMed ID: 27035159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
    Fava M; Dirks B; Freeman MP; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
    J Clin Psychiatry; 2019 Sep; 80(6):. PubMed ID: 31556975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder.
    Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M
    J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.
    Dunner DL; Amsterdam JD; Shelton RC; Loebel A; Romano SJ
    J Clin Psychiatry; 2007 Jul; 68(7):1071-7. PubMed ID: 17685744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
    Rosenthal JZ; Boyer P; Vialet C; Hwang E; Tourian KA
    J Clin Psychiatry; 2013 Feb; 74(2):158-66. PubMed ID: 23473348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
    Tummala R; Desai D; Szamosi J; Wilson E; Hosford D; Dunbar G; Eriksson H
    J Clin Psychopharmacol; 2015 Feb; 35(1):77-81. PubMed ID: 25514064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
    Karp JF; Whyte EM; Lenze EJ; Dew MA; Begley A; Miller MD; Reynolds CF
    J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
    J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher dose L-methylfolate may be an effective adjunctive therapy for adults with major depression who have inadequate response to SSRIs.
    Roberts SH; Tranter R
    Evid Based Ment Health; 2013 Aug; 16(3):75. PubMed ID: 23625145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.